Table 1.
Main characteristics of the selected studies.
| First author | Year | Country | Cancer type | N (M/F) | High expression | Follow-up (months) | Outcome | HR (95% CI) | Quality score |
|---|---|---|---|---|---|---|---|---|---|
| Fu [35] | 2019 | China | HCC | 122 (79/43) | >Median expression | 60∗ | OS | 2.126 (1.273-8.775) | 8 |
| Ruan [36] | 2018 | China | OS | 50 (32/18) | >Median expression | 70∗ | OS | 1.32 (0.88-1.97) | 8 |
| Yan [10] | 2018 | China | OS | 40 | NR | 60∗ | OS/PFS | 0.69 (0.22-2.21)/1.42 (0.55-3.62) | 7 |
| Xu [37] | 2018 | China | CCA | 60 (27/33) | Median value: 2.95-fold | 60∗ | OS | 2.391 (1.024-5.583) | 8 |
| Fu [38] | 2018 | China | PA | 74 | >Median expression | 40∗ | OS | 1.56 (1.06-2.29) | 7 |
| Bai [39] | 2018 | China | CCA | 106 (78/28) | Above the cut-off value | 72∗ | OS/PFS | 3.10 (2.17-4.43)/3.31 (2.32-4.72) | 8 |
| Chen [40] | 2017 | China | HCC | 60 (48/12) | >Median expression | 40∗ | OS | 2.46 (1.71-3.53) | 8 |
| Ozawa [24] | 2017 | USA/Japan | CRC | 300 | NR | 60∗ | OS/RFS | 2.40 (1.22-4.59)/2.39 (1.10-5.08) | 7 |
| Wu [22] | 2017 | China | GC | 208 (124/84) | >twofold change | 85 | OS/DFS | 1.214 (0.898-1.882)/1.687 (0.833-1.896) | 8 |
| Huang [20] | 2017 | China | RCC | 61 (34/27) | >Median expression | 60∗ | OS | 3.02 (1.14-7.96) | 8 |
| Ma [41] | 2017 | China | OC | 62 (40/22) | >eightfold | 60∗ | OS | 1.60 (1.03-2.47) | 8 |
| Deng [42] | 2017 | China | BC | 120 | >Median expression | 100∗ | OS | 1.89 (1.36-2.63) | 8 |
| Chen [18] | 2016 | China | SCLC | 112 (67 : 45) | >Median expression | 60∗ | OS | 1.66 (1.22-2.27) | 7 |
| Wang [23] | 2016 | China | GC | 108 (64 : 44) | >Median expression | 70∗ | OS/DFS | 2.108 (1.442-3.202)/2.305 (1.554-3.418) | 8 |
| Huang [43] | 2016 | China | ORC | 109 | >Median expression | 60∗ | OS/DFS | 2.938 (1.526-5.873)/1.74 (1.27-2.39) | 8 |
| Zheng [21] | 2016 | China | PC | 96 | >Median expression | 60∗ | OS/PFS | 2.292 (1.370-3.528)/2.276 (1.199-2.768) | 7 |
| Zhang [16] | 2015 | China | EC | 229 (170/59) | >Median expression | 80∗ | OS | 1.432 (1.005-2.041) | 8 |
| Wang [17] | 2015 | China | GC | 85 (41/44) | >Mean expression | 60∗ | OS/PFS | 2.405 (1.194-5.417)/2.315 (1.097-5.283) | 8 |
| Cai [44] | 2015 | China | BC | 67 | >eightfold | 60∗ | OS | 3.57 (1.77-7.21) | 7 |
| Chen [45] | 2015 | China | CC | 123 | >Mean expression | 60∗ | OS/PFS | 2.813 (1.504-6.172)/3.072 (1.716-8.174) | 8 |
N (M/F): number (male/female); HR: hazard ratio; CI: confidence interval; HCC: hepatocellular carcinoma; OS: osteosarcoma; CCA: cholangiocarcinoma; PA: pituitary adenomas; CRC: colorectal carcinoma; GC: gastric carcinoma; RCC: renal cell carcinoma; OC: oral carcinoma; BC: breast cancer; SCLC: small cell lung cancer; ORC: ovarian cancer; PC: prostate cancer; EC: esophageal carcinoma; CC: cervical cancer; OS: overall survival; PFS: progression-free survival; RFS: relapse-free survival; DFS: disease-free survival; NR: not reported; ∗Approximate times extracted from survival curve.